US5707618A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Adenovirus vectors for gene therapy
Assignee: Genzyme Corp
•
Filing: 1995-03-24
•
Granted: 1998-01-13
•
Expires: 2015-03-24
Abstract
Abstract The present invention relates to novel adenovirus vectors for use in gene therapy which are designed to prevent the generation of replication-competent adenovirus (RCA) during in vitro propagation and clinical use. The invention also provides methods for the production of the novel virus vectors. These vectors maximize safety for clinical applications in which adenovirus vectors are used to transfer genes into recipient cells for gene therapy.
Inventors
- 👤 Donna Armentano
- 👤 Helen Romanczuk
- 👤 Samuel Charles Wadsworth
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-02 17:40
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/63; C12N15/79; C12N15/85; C12N15/86; C07; C07K; C07K14/00; C07K14/435; C07K14/46; C07K14/47; C07K14/4701; C07K14/4712; A; A61; A61K; A61K48/00; C12N2710/00; C12N2710/00011; C12N2710/10011; C12N2710/10311; C12N2710/10341; C12N2710/10343
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
61 words
A recombinant adenovirus vector having a deleted E1 region of the adenovirus genome, into which a heterologous gene has been inserted, and in which the protein IX gene has been relocated in the adenovirus genome to a location thereof other than the location in which said protein IX gene normally resides, such that generation of replication-competent adenoviruses is minimized or eliminated.
Claim 2
Dependent Claim
61 words
A recombinant adenovirus vector having a deleted E1 region of the adenovirus genome, into which a heterologous gene has been inserted, and in which the protein IX gene has been relocated in the adenovirus genome to a location thereof other than the location in which said protein IX gene normally resides, such that generation of replication-competent adenoviruses is minimized or eliminated.
Claim 3
Dependent Claim
19 words
The vector of claim 1 in which one or more open reading frames of the E4 region is deleted.
Claim 4
Dependent Claim
17 words
The vector of claim 2, in which the protein IX gene is relocated to the E4 region.
Claim 5
Dependent Claim
14 words
The vector of claim 2, in which ORF6 of the E4 region is retained.
Claim 6
Dependent Claim
18 words
The vector of claim 4, in which the protein IX gene is inserted adjacent to the ORF6 gene.
Claim 7
Dependent Claim
15 words
The vector of claim 1, in which the heterologous gene is a gene encoding CFTR.
Claim 8
Dependent Claim
26 words
The vector of claim 1 in which the heterologous gene is operably linked to a eucaryotic promoter, so as to allow for expression of the gene.
Claim 9
Dependent Claim
20 words
The vector of claim 1, in which the adenovirus is selected from among adenovirus serotypes 2, 4, 5 and 7.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-01-12 | 2001-07-14 | 2002-01-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-01-12 | 2005-07-14 | 2006-01-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-01-12 | 2009-07-14 | 2010-01-13 | $7700.00 | Window Closed / Lapsed |